



Syncom Formulations (India) Limited

CIN No.: L24239MH1988PLC047759

A WHO-GMP & ISO 9001-2015 Certified Company

SYNCOM/SE/2018-19

14th August, 2018

online filing at www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Ltd.
Dalal Street, Fort,
MUMBAI-400001

BSE CODE: 524470

Subject: Submission of the Standalone Unaudited Financial Results and the Limited Review Report of the Auditors for the Quarter ended 30th June, 2018 u/r 33 of the SEBI (LODR Regulations, 2015.

Dear Sir,

This has in continuation of our letter No. SYNCOM/SE/2017-18 dated 3rd August, 2018 regarding intimation for Board meeting for consideration and approval of the Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2018.

We are pleased to submit the followings;

1. Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2018 which was considered and approved by the Board at their Meeting held on the 14th August, 2018 in accordance with the Regulation 33 of the SEBI (LODR) Regulations, 2015.
2. Limited Review Report given by the Auditors on the Standalone Unaudited Financial Results of the Company for the Quarter Ended 30th June, 2018 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, which was also considered and approved by the Audit Committee and Board of Directors of the Company at their meeting held on 14th August, 2018

We are also in the process to file the aforesaid Revised Audited Financial Results in the XBRL form and the same shall also be hosted at the website of the Company www.sfil.in.

The above results being given for publication in the English and Marathi Newspapers.

You are requested to take on records the above said un-audited financial results and the Limited Review Report for your reference and record.

Thanking You,
Yours Faithfully,

FOR, SYNCOM FORMULATIONS (INDIA) LTD.

Karishma
CS KARISHMA KAKKAR
COMPANY SECRETARY &
COMPLIANCE OFFICER
Encl.: a/a



Bringing a smile on every face...



SYNCOM FORMULATIONS (INDIA) LIMITED

REGD. OFF.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI-400 093
WORKS : 256-257, Sector-1, Pithampur (Dhar), E-mail: info@sfil.in - CIN: L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2018

S. No.	Particulars (Rs. in Lakhs)	Quarter Ended		Year Ended	
		30.06.2018 (Unaudited)	31.03.2018 (Audited)*	30.06.2017 (Unaudited)	31.03.2018 (Audited)
1	Income from Operations				
	(a) Net sales	3291.69	3922.58	4102.53	15863.16
2	Other Income	126.21	138.68	70.99	443.96
3	Total Income	3417.90	4061.26	4173.52	16307.12
4	Expenses				
	(a) Cost of Material Consumed	2086.61	2011.21	2067.91	7760.33
	(b) Purchase of stock in trade	451.82	920.58	1210.85	3200.51
	(c) Changes in inventories of finished goods, Work in progress and stock in trade	(246.25)	(132.57)	(408.75)	(65.85)
	(d) Employee Benefit Expenses	364.83	389.62	363.85	1504.43
	(e) Finance Cost	6.45	4.64	5.24	26.57
	(f) Depreciation and amortization Expenses	99.39	102.98	90.69	372.98
	(g) Other Expenses	464.96	526.37	529.02	2296.50
	Total Expenses (4)	3227.81	3822.83	3858.81	15095.47
5	Profit/ (loss) before exceptional item and tax (3-4)	190.09	238.43	314.71	1211.65
6	Exceptional Items	0.00	10.15	0.00	10.15
7	Profit before tax (5-6)	190.09	228.28	314.71	1201.50
8	Tax Expenses				
	(a) Current Tax	40.00	65.42	104.00	306.79
	(b) Deferred Tax	(55.00)	(10.02)	8.25	29.98
9	Profit/ (loss) for the period from continuing operations (7-8)	205.09	172.88	202.46	864.73
10	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
11	Tax Expenses of discontinuing Operations (after Tax)	0.00	0.00	0.00	0.00
12	Profit/ (loss) for the period from Discontinuing operations (after Tax) (10-11)	0.00	0.00	0.00	0.00
13	Profit/ (loss) for the period (9+12)	205.09	172.88	202.46	864.73
14	Other Comprehensive Income :				
A	(i) Items that will not be reclassified to P & L	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to items that will not be reclassified to Profit & Loss	0.00	0.00	0.00	0.00
B	(i) Items that will be reclassified to P & L	(28.39)	(79.06)	(2.37)	101.29
	(ii) Income tax relating to items that will be reclassified to Profit & Loss	0.00	0.00	0.00	0.00
15	Total comprehensive income for the period (14+15) (Comprising Profit/(loss) and other comprehensive Income for the period)	176.70	93.81	200.09	966.02
16	Paid up Equity Capital	7806.52	7806.52	7806.52	7806.52
17	Other Equity	---	---	---	4387.73
18	Earning Per Share (of Rs.1/- each) for continuing Operations				
	(a) Basic	0.02	0.01	0.03	0.12
	(b) Diluted	0.02	0.01	0.03	0.12
19	Earning Per Share (of Rs.1/- each) for Dis-continuing Operations				
	(a) Basic	0.00	0.00	0.00	0.00
	(b) Diluted	0.00	0.00	0.00	0.00
20	Earning Per Share (of Rs. 1/- each) for Dis-continuing Operations and continuing operations				
	(a) Basic	0.02	0.01	0.03	0.12
	(b) Diluted	0.02	0.01	0.03	0.12

SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY RESULTS

S. No.	Particulars (Rs. in Lakhs)	Quarter Ended			Year Ended
		30.06.2018 (Unaudited)	31.03.2018 (Audited)*	30.06.2017 (Unaudited)*	31.03.2018 (Audited)
1	Segment Revenue				
	(a) Pharmaceuticals Drugs & Formulations	2951.47	2998.98	3090.16	13690.71
	(b) Trading of Commodities	382.23	970.60	1030.10	2320.98
	(c) Renting of Property	84.20	91.68	53.26	295.43
	Total	3417.90	4061.26	4173.52	16307.12
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00
	Net Sales/Income from Operations	3417.90	4061.26	4174.00	16307.12
2	Segment Results (Profit)/+Loss(-) before tax and interest from each Segment				
	(a) Pharmaceuticals Drugs & Formulations	98.45	120.53	190.53	820.70
	(b) Trading of Commodities	13.89	30.86	76.16	122.08
	(c) Renting of Property	84.20	91.68	53.26	295.43
	Total	196.54	243.07	319.95	1238.21
	Less: (i) Interest	6.45	4.64	5.24	26.57
	(ii) Other Un-allocable Expenditure (net off Un-allocable Income)	0.00	10.15	0.00	10.15
	Total Profit Before Tax	190.09	228.28	314.71	1201.49
3	Capital Employed (Segment Assets - Segment Liabilities)				
	(a) Pharmaceuticals Drugs & Formulations	8354.16	7954.41	8598.70	7954.41
	(b) Trading of Commodities	99.27	220.30	468.24	220.30
	(c) Renting of Property	3917.52	4019.55	2870.97	4019.55
	(d) Unallocated	0.00	0.00	0.00	0.00
	Total Capital Employed	12370.95	12194.26	11937.91	12194.26

Notes:

- The above results were reviewed by the Audit Committee and then approved by the Board at their respective meetings held on 14.08.2018.
- The above financial results are prepared in compliance with Indian Accounting Standards ("IND-AS") as notified under section 133 of the Companies Act 2013 ("the Act") [Companies (Indian Accounting Standards) rules 2015] as amended accordingly. These financial results have been prepared in accordance with the recognition and measurement principals let down in IND AS 34 "Interim Financial reporting" prescribed U/s 133 of the Companies Act 2013 read with the relevant rules there under.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the statutory auditors have been completed for the quarter ended 30th June 2018. The report does not have any impact on the above results and notes which needs explanation.
- The Company is operating in three segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of commodities and (c) Renting of property, particulars for segment wise results are as above.
- *The figures of quarter ended 31.03.2018 are the balancing figures between audited figures in respect of full financial year & the published year to date figures up to the 3rd quarter of that financial year 2017-18.
- Ind AS 115 "Revenue from contract with customers" is mandatory for reporting periods beginning on or after April 1, 2018 and replaces the existing revenue recognition requirements. Based on management assessment, the adoption of the standard did not have any material impact to the financial results of the company.
- Previous period figures have been regrouped/reclassified where necessary.

By Order of The Board of Directors
For Syncom Formulations (India) Ltd.

Kedarnath Rankda
Chairman & Whole-Time Director
DIN: 00023050

Place : Indore
Dated : 14/08/2018



SANJAY MEHTA & ASSOCIATES

Chartered Accountants

338, Saket Nagar, Indore - 452 018

Phone/Telefax : 0731-4274391, 2563625

E-mail:sanjaymehta.associates@gmail.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS


TO
THE BOARD OF DIRECTORS
SYNCOM FORMULATIONS (INDIA) LTD.

1. We have reviewed the accompanying statement of Unaudited Financial Results of **Syncom Formulations (India) Limited ("the Company")**, for the Quarter ended June 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as notified by Circular No. CIRJCFD/FAAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or it contains any material misstatement.

For Sanjay Mehta & Associates
Chartered Accountants
FRN 011524C


Manish Mittal
(Partner)
M.no. 079452



Date: 14th August 2018
Place: Indore